Is ADMA BIOLOGICS, INC. (ADMA) Halal?

NASDAQ Healthcare United States $2.2B
✓ HALAL
Confidence: 95/100
ADMA BIOLOGICS, INC. (ADMA) is Halal under all 5 major Shariah screening standards. With a debt ratio of just 2.2% against the AAOIFI threshold of 30%, ADMA BIOLOGICS, INC. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 2.2%
/ 30%
2.4%
/ 30%
4.3%
/ 30%
0.37%
/ 5%
✓ HALAL
DJIM 2.2%
/ 33%
2.4%
/ 33%
4.3%
/ 33%
0.37%
/ 5%
✓ HALAL
MSCI 12.8%
/ 33%
14.0%
/ 33%
25.4%
/ 33%
0.37%
/ 5%
✓ HALAL
S&P 2.2%
/ 33%
2.4%
/ 33%
4.3%
/ 33%
0.37%
/ 5%
✓ HALAL
FTSE 12.8%
/ 33%
14.0%
/ 33%
25.4%
/ 50%
0.37%
/ 5%
✓ HALAL

Financial Highlights

P/E Ratio
15.4
Forward: 6.7
EPS
$0.60
P/B Ratio
4.6
EV/EBITDA
11.0
EV: $2.2B
Revenue
$510M
Growth: 18.4%
Beta
0.6
Low volatility
Current Ratio
6.7

Profitability

Gross Margin 57.4%
Operating Margin 45.1%
Net Margin 28.8%
Return on Equity (ROE) 35.6%
Return on Assets (ROA) 21.5%

Cash Flow & Balance Sheet

Operating Cash Flow$50M
Free Cash Flow$28M
Total Debt$80M
Debt-to-Equity16.7
Current Ratio6.7
Total Assets$624M

Price & Trading

Last Close$8.29
50-Day MA$15.63
200-Day MA$16.84
Avg Volume2.9M
Beta0.6
52-Week Range
$7.21
$25.67

About ADMA BIOLOGICS, INC. (ADMA)

CEO
Mr. Adam S. Grossman
Employees
640
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$2.2B
Currency
USD

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Purification Calculator

As a halal stock with 0.37% impermissible income, you need to purify your dividends.

Enter your dividends to calculate purification amount

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is ADMA BIOLOGICS, INC. (ADMA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), ADMA BIOLOGICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is ADMA BIOLOGICS, INC.'s debt ratio?

ADMA BIOLOGICS, INC.'s debt ratio is 2.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.8%.

Does ADMA BIOLOGICS, INC. require dividend purification?

Yes, ADMA BIOLOGICS, INC. has an impermissible income ratio of 0.37%, which means 0.37% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.

What are ADMA BIOLOGICS, INC.'s key financial metrics?

ADMA BIOLOGICS, INC. has a market capitalization of $2.2B, trailing P/E ratio of 15.4, and revenue of $510M. The company maintains a gross margin of 57.4% and a net margin of 28.8%. Return on equity stands at 35.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.